Recursion extends cash runway into 2028, beats as AI platform yields first clinical proof

 

Recursion extends cash runway into 2028 and posts Q1 2026 EPS -$0.22 beat as AI platform yields first clinical proof

• REC-4881 showed clinical proof-of-concept in FAP; FDA engagement underway on registrational pathway.
• Q1 2026 non-GAAP EPS -$0.22 improved 56% YoY and beat estimates.
• Q1 2026 revenue was $6.3M, down 57% YoY and below about $16M forecast for the quarter.
• Cash and equivalents $665m, with operating runway guided through early 2028 without new financing.
• Cash operating expenses down 30% YoY; 2026 cash opex guidance below $390m reaffirmed.
• Q1 2026 net loss totaled $117.5M, versus reported quarterly revenue of $6.5M.
• Early REC-1245 Phase I data show good tolerability, target engagement, and dose-dependent exposure.
• REC-4539 LSD1 inhibitor dosed first patient; aims to reduce class-limiting thrombocytopenia.
• Company expects clinical readouts for all wholly owned clinical programs over next 12–18 months.
• Platform efficiency claims: ~90% fewer compounds synthesized and roughly 2x faster to candidates.
• ClinTech tools reportedly cut trial enrollment times 30–60% and broaden eligible patient pools.
• Partnerships have generated $500m+ inflows; fifth Sanofi milestone achieved, more opt-ins anticipated.
• Main concern: long path and regulatory uncertainty before AI-derived pipeline converts into commercial revenue.
• Mixed quarter, driven by strong AI-driven pipeline and platform progress offset by continued pre-revenue status.

https://finviz.com/quote?t=RXRX&p=d